Evidence map›Paper›PMID 40901880›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Manipulating anthracyclines for deeper tissue penetration and implications for glycolytic tissues.

Erik R Abels, Esther Ter Linden, Jos H T Rohling, Lennard M Voortman, Lennert Janssen, Marten Hornsveld, Herman S Overkleeft, Sabina Y van der Zanden, Marike L D Broekman, Jacques Neefjes

Erratum issuedAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Erik R Abels *Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Esther Ter Linden *Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Jos H T RohlingDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.ORCID 0000-0001-5721-2715
Lennard M VoortmanDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Lennert JanssenDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Marten HornsveldDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Herman S OverkleeftLeiden Institute of Chemistry, Faculty of Science, Leiden University, Leiden 2333 RC, The Netherlands.
Sabina Y van der ZandenDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.ORCID 0000-0001-5587-1514
Marike L D BroekmanDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Jacques NeefjesDepartment of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.ORCID 0000-0001-6763-2211

Funding

Hersenstichting (Hersenstichting Nederland) HS2000NWO | Exacte en Natuurwetenschappen (ENW) ICI0026
6 · The paper itself

Abstract

How drugs penetrate tissues is poorly understood yet important, since drugs that fail to reach their target will be ineffective. We followed the fate of anthracycline cancer drugs at high resolution by exploiting their intrinsic fluorescence. In a cell-based spheroid model, the soluble compound fluorescein penetrates the entire spheroid, unlike hydrophobic fluorescent lipids, which only enter the outermost cell layer. Anthracyclines have intermediate hydrophobicity. They enter the nucleus of a few outer cell layers at neutral pH, but penetrate the spheroids more deeply under acidic conditions, with a reduction in cell entry and cytotoxicity. The glycolytic conditions that prevail in the tumor microenvironment may thus limit cell entry and contribute to anthracycline drug resistance. We evaluated a library of anthracycline variants to determine the physicochemical properties related to tissue penetration depth. We find that this is determined by only three chemical properties: molar refractivity, topological polar surface area, and water solubility. Our findings suggest that modifications of anthracyclines may improve access and activity to deeply tissue-embedded targets such as pancreatic cancer.

Indexed as

AnthracyclinesAntineoplastic AgentsGlycolysisCell Line, TumorHumansSpheroids, CellularTumor MicroenvironmentAnthracyclinesAntineoplastic Agentsanthracyclinesdoxorubicindrug resistanceglycolysistissue penetration

Identifiers

PMID40901880
PMCPMC12435226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.